Skip to main content


Full Schedule

Full Schedule

  • Thursday, October 7, 2021
  • 10:00 AM – 11:05 AM EDT
    Opening Panel: Innovations Worth Keeping: Positive Practice Changes After the COVID-19 Pandemic
  • 10:00 AM – 8:15 PM EDT
    Industry Encore Posters
  • 11:15 AM – 12:00 PM EDT
    Clinically Relevant Drug Interactions in the Cancer Setting
  • 12:15 PM – 1:00 PM EDT
    Considerations for the Treatment of Patients With Lung Cancer: Resectable NSCLC and Unresectable Stage III NSCLC - AstraZeneca
  • 1:00 PM – 1:45 PM EDT
    Moderated Clinical Posters
  • 1:45 PM – 2:15 PM EDT
    Micro-Community Meet Ups
  • 2:15 PM – 3:00 PM EDT
    Immunotherapies for the Treatment of Triple-Negative Breast Cancer
  • 3:15 PM – 4:00 PM EDT
    Managing Immune-related Adverse Events with Checkpoint Inhibitors - GSK
  • 4:15 PM – 4:45 PM EDT
    Updates in the Diffuse Large B-Cell Lymphoma Treatment Landscape
  • 5:15 PM – 6:00 PM EDT
    Product Theater
  • 6:15 PM – 7:15 PM EDT
    Opening Panel: Innovations Worth Keeping: Positive Practice Changes After the COVID-19 Pandemic
  • 7:30 PM – 8:15 PM EDT
    Clinically Relevant Drug Interactions in the Cancer Setting
  • Friday, October 8, 2021
  • 8:30 AM – 9:45 AM EDT
    Independent Satellite Symposium: Approaches for Optimal Molecular Testing, Treatment, and Management of NSCLC and Accompanying Driver Mutations
  • 10:00 AM – 10:45 AM EDT
    Cardio-Oncology Considerations in Oncologic Treatment Decisions
  • 10:00 AM – 6:30 PM EDT
    Industry Encore Posters
  • 11:00 AM – 11:45 AM EDT
    An Overview of Reblozyl (luspatercept-aamt) - Bristol Myers Squibb
  • 12:00 PM – 1:00 PM EDT
    The Mary Pazdur Award Presentation Followed by the Keynote Interview: Pull Up a Seat: Engaging Patients as Empowered Partners in Health Equity Transformation
  • 1:15 PM – 1:45 PM EDT
    Mental Health in the Oncology Setting: General Considerations and Treatment Tips
  • 2:00 PM – 2:45 PM EDT
    Product Theater
  • 3:00 PM – 3:30 PM EDT
    Thriving, Not Just Surviving: Recognizing Burnout and Simple Tips to Start Feeling Better
  • 3:45 PM – 4:30 PM EDT
    Product Theater
  • 4:45 PM – 5:30 PM EDT
    Cardio-Oncology Considerations in Oncologic Treatment Decisions
  • 5:45 PM – 6:30 PM EDT
    Keynote Interview: Pull Up a Seat: Engaging Patients as Empowered Partners in Health Equity Transformation
  • 7:00 PM – 8:15 PM EDT
    Independent Satellite Symposium: Approaches for Optimal Molecular Testing, Treatment, and Management of NSCLC and Accompanying Driver
  • Saturday, October 9, 2021
  • 10:00 AM – 11:00 AM EDT
    New Drug Updates: Hematologic Malignancies
  • 10:00 AM – 8:45 PM EDT
    Industry Encore Posters
  • 11:15 AM – 12:00 PM EDT
    Product Theater
  • 12:15 PM – 1:00 PM EDT
    A Call to Action: The Role of the Oncology AP in Equitable Cancer Care
  • 1:00 PM – 1:45 PM EDT
    Moderated Clinical Posters
  • 1:30 PM – 2:30 PM EDT
    Conversation Circles: Building a Resume/CV that Rises to the TOP
  • 1:30 PM – 2:30 PM EDT
    Conversation Circles: Putting Equitable Cancer Care into Action
  • 2:45 PM – 3:30 PM EDT
    Direct Oral Anticoagulants and Cancer Thrombosis: What APs Need to Know
  • 3:45 PM – 4:30 PM EDT
    BLENREP REMS: Real World Implementation and Best Practices - GSK
  • 4:45 PM – 5:30 PM EDT
    Multidisciplinary Management of Pancreatic Cancer
  • 5:45 PM – 6:30 PM EDT
    Clinical Cases in Polycythemia Vera: When to Intervene With Jakafi® (ruxolitinib) | Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea - Incyte Corporation
  • 6:45 PM – 7:45 PM EDT
    New Drug Updates: Hematologic Malignancies
  • 8:00 PM – 8:45 PM EDT
    A Call to Action: The Role of the Oncology AP in Equitable Cancer Care
  • Sunday, October 10, 2021
  • 8:30 AM – 9:45 AM EDT
    Independent Satellite Symposium: CLL/SLL: Managing Adverse Events Associated with BTK Inhibitor Therapy
  • 10:00 AM – 10:45 AM EDT
    Biomarker Jeopardy
  • 10:00 AM – 6:15 PM EDT
    Industry Encore Posters
  • 11:00 AM – 11:45 AM EDT
    Clinical Trial Evidence for a CDK4/6 Inhibitor Combination Therapy Complemented by an Evaluation of Real-World Effectiveness - Pfizer Oncology
  • 12:00 PM – 12:45 PM EDT
    Updates in the Management of Renal Cell Carcinoma
  • 1:00 PM – 1:30 PM EDT
    Updates in Cholangiocarcinoma
  • 1:45 PM – 2:30 PM EDT
    Product Theater
  • 2:45 PM – 3:15 PM EDT
    The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
  • 3:30 PM – 4:15 PM EDT
    Clinical Management of Patients with CABOMETYX® (cabozantinib) + OPDIVO ® (nivolumab) - Exelixis
  • 4:30 PM – 5:15 PM EDT
    Biomarker Jeopardy
  • 5:30 PM – 6:15 PM EDT
    Updates in the Management of Renal Cell Carcinoma
  • 6:30 PM – 7:45 PM EDT
    Independent Satellite Symposium: CLL/SLL: Managing Adverse Events Associated with BTK Inhibitor Therapy
  • Wednesday, October 13, 2021
  • 10:30 AM – 11:45 AM EDT
    Independent Satellite Symposium: Navigating the Expanding Treatment Landscape in Metastatic Urothelial Cancer: Novel Targeted Therapies
  • 12:00 PM – 12:30 PM EDT
    APSHO Annual Member Meeting (Open to Members Only)
  • 12:30 PM – 4:30 PM EDT
    Braindates
  • 5:00 PM – 6:15 PM EDT
    Independent Satellite Symposium: Navigating the Expanding Treatment Landscape in Metastatic Urothelial Cancer: Novel Targeted Therapies
  • Thursday, October 14, 2021
  • 10:00 AM – 11:15 AM EDT
    New Drug Updates: Solid Tumors
  • 10:00 AM – 7:30 PM EDT
    Industry Encore Posters
  • 11:15 AM – 12:00 PM EDT
    Plan for Tomorrow Today, Managing patients with KRAS G12C-mutated NSCLC - Amgen Oncology
  • 12:15 PM – 1:00 PM EDT
    Herbal Medicine and Supplements: Friend or Foe?
  • 12:45 PM – 1:15 PM EDT
    Micro-Community Meet Ups
  • 12:45 PM – 1:30 PM EDT
    Moderated Clinical Posters
  • 1:30 PM – 2:15 PM EDT
    New Frontiers: The Role of CAR T-Cell Therapy in Multiple Myeloma
  • 2:30 PM – 3:15 PM EDT
    PEMAZYRE® (pemigatinib): The First FDA-Approved Treatment for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma (CCA) with an FGFR2 Fusion or Rearrangement - Incyte Corporation
  • 3:30 PM – 4:15 PM EDT
    Survivorship Care Challenges: Navigating Changing Concerns
  • 4:30 PM – 5:15 PM EDT
    AML Patient Cases and Supporting Data - Bristol Myers Squibb
  • 5:30 PM – 6:45 PM EDT
    New Drug Updates: Solid Tumors
  • 6:45 PM – 7:30 PM EDT
    Herbal Medicine and Supplements: Friend or Foe?
  • 7:30 PM – 8:45 PM EDT
    Five Eyes: A Virtual Game Event
  • Friday, October 15, 2021
  • 8:30 AM – 9:45 AM EDT
    Independent Satellite Symposium: Navigating the Evolving Treatment Landscape in Prostate Cancer: A Focus on Novel Anti-androgen Therapy
  • 10:00 AM – 11:00 AM EDT
    Multidisciplinary Management of Resectable Early-Stage Non-Small Cell Lung Cancer
  • 10:00 AM – 7:30 PM EDT
    Industry Encore Posters
  • 11:15 AM – 12:00 PM EDT
    Combining the HER2+ Breast Cancer Antibodies You Know in One Faster Mode of Administration - Genentech
  • 12:15 PM – 1:00 PM EDT
    Identifying the Leader in You
  • 1:15 PM – 2:00 PM EDT
    Molecular Testing for Hematologic Malignancies
  • 2:15 PM – 3:00 PM EDT
    A Treatment Option for the Management of Certain Patients with First-Line Non-Small Cell Lung Cancer - Bristol Myers Squibb
  • 3:15 PM – 4:15 PM EDT
    Lung Cancer Biomarker Speak: Teach Me the Language
  • 4:30 PM – 5:15 PM EDT
    Treating Advanced Prostate Cancer - Astellas and Pfizer
  • 5:30 PM – 6:30 PM EDT
    Multidisciplinary Management of Resectable Early-Stage Non-Small Cell Lung Cancer
  • 6:45 PM – 7:30 PM EDT
    Identifying the Leader in You
  • 7:45 PM – 9:00 PM EDT
    Independent Satellite Symposium: Navigating the Evolving Treatment Landscape in Prostate Cancer: A Focus on Novel Anti-androgen Therapy
  • Saturday, October 16, 2021
  • 10:00 AM – 11:00 AM EDT
    An AP Perspective on Infusion Reactions in the Era of Immunotherapy
  • 10:00 AM – 8:30 PM EDT
    Industry Encore Posters
  • 11:15 AM – 12:00 PM EDT
    Sarclisa + KD: An Anti-CD38 Combination for the Treatment of Multiple Myeloma Patients as Early as First Relapse - Sanofi Genzyme
  • 12:00 PM – 1:00 PM EDT
    Conversation Circles: Emotional Intelligence: An AP Growth Tool
  • 12:00 PM – 1:00 PM EDT
    Conversation Circles: Professional Bullying
  • 1:15 PM – 2:00 PM EDT
    Role of the Advanced Practitioner in the Management of Oral Chemotherapy for Adults With Acute Myeloid Leukemia
  • 2:00 PM – 2:30 PM EDT
    Moderated Clinical Posters
  • 2:30 PM – 3:15 PM EDT
    The Advanced Practice Role in Clinical Trials: Past, Present, and Future
  • 3:30 PM – 4:15 PM EDT
    Advances in targeted therapy for CLL: Efficacy and Practical Management of BCL-2 inhibitors - AbbVie Medical Affairs
  • 4:30 PM – 5:15 PM EDT
    New Drug Updates: Investigational Therapeutics in the Pipeline
  • 5:30 PM – 6:15 PM EDT
    In Adult and Pediatric Patients 12 Years and Older with Chronic GVHD, Intervene with Jakafi® (ruxolitinib) At the First Sign of Initial Systemic Treatment Failure - Incyte Corporation
  • 6:30 PM – 7:30 PM EDT
    An AP Perspective on Infusion Reactions in the Era of Immunotherapy
  • 7:45 PM – 8:30 PM EDT
    Role of the Advanced Practitioner in the Management of Oral Chemotherapy for Adults With Acute Myeloid Leukemia
  • Sunday, October 17, 2021
  • 8:30 AM – 9:45 AM EDT
    Independent Satellite Symposium: Metastatic HER2-Positive Breast Cancer: Newer and Emerging Treatment Considerations and Personalized Therapies
  • 10:00 AM – 11:00 AM EDT
    Oncology Urgent Care Clinics: Understanding Utilization and Best Practices
  • 10:00 AM – 7:45 PM EDT
    Industry Encore Posters
  • 11:15 AM – 12:00 PM EDT
    Educate Your Patients on IMBRUVICA® (ibrutinib) Treatment - Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
  • 12:15 PM – 1:15 PM EDT
    Race, Social Determinants of Health, and Cancer: How Can APs Address and Improve Patient Outcomes?
  • 1:30 PM – 2:15 PM EDT
    The Critical Role of Nutrition and Exercise Optimization in the Patient With Cancer
  • 2:30 PM – 3:15 PM EDT
    Raising Awareness: What the Patient Care Team Should Know About Metastatic Non-Small Cell Lung Cancer (mNSCLC) With EGFR Exon 20 Insertion Mutations - Janssen
  • 3:30 PM – 4:15 PM EDT
    Multidisciplinary Tumor Boards and Guiding Patient Care: The AP Role
  • 4:30 PM – 5:15 PM EDT
    Monjuvi (Tafasitamab-Cxix) For Use As Second-Line Therapy In Adult Patients With R/R DLBCL, In Combination With Lenalidomide - Incyte Corporation and MorphoSys US Inc.
  • 5:30 PM – 6:30 PM EDT
    Oncology Urgent Care Clinics: Understanding Utilization and Best Practices
  • 6:45 PM – 7:45 PM EDT
    Race, Social Determinants of Health, and Cancer: How Can APs Address and Improve Patient Outcomes?
  • 8:00 PM – 9:15 PM EDT
    Independent Satellite Symposium: Metastatic HER2-Positive Breast Cancer: Newer and Emerging Treatment Considerations and Personalized Therapies